Florida Senate - 2025 SB 1360
By Senator Leek
7-00152A-25 20251360__
1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; excepting from the Schedule I controlled
4 substance xylazine drug products approved by the
5 United States Food and Drug Administration labeled for
6 and prescribed or dispensed by veterinarians; adding
7 xylazine as a Schedule III controlled substance;
8 excepting from the Schedule III controlled substance
9 xylazine specified drug products approved by the
10 United States Food and Drug Administration; defining
11 the term “person”; amending s. 893.13, F.S.; providing
12 criminal penalties and requiring a mandatory minimum
13 term of imprisonment if a person sells, manufactures,
14 or delivers or possesses with intent to sell,
15 manufacture, or deliver xylazine; amending s. 893.135,
16 F.S.; creating the offense of trafficking in xylazine;
17 providing criminal penalties and requiring a mandatory
18 minimum term of imprisonment and fines based on the
19 quantity of the controlled substance involved in the
20 offense; providing an effective date.
21
22 Be It Enacted by the Legislature of the State of Florida:
23
24 Section 1. Paragraph (c) of subsection (1) and paragraph
25 (a) of subsection (3) of section 893.03, Florida Statutes, are
26 amended to read:
27 893.03 Standards and schedules.—The substances enumerated
28 in this section are controlled by this chapter. The controlled
29 substances listed or to be listed in Schedules I, II, III, IV,
30 and V are included by whatever official, common, usual,
31 chemical, trade name, or class designated. The provisions of
32 this section shall not be construed to include within any of the
33 schedules contained in this section any excluded drugs listed
34 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
35 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
36 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
37 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
38 Anabolic Steroid Products.”
39 (1) SCHEDULE I.—A substance in Schedule I has a high
40 potential for abuse and has no currently accepted medical use in
41 treatment in the United States and in its use under medical
42 supervision does not meet accepted safety standards. The
43 following substances are controlled in Schedule I:
44 (c) Unless specifically excepted or unless listed in
45 another schedule, any material, compound, mixture, or
46 preparation that contains any quantity of the following
47 hallucinogenic substances or that contains any of their salts,
48 isomers, including optical, positional, or geometric isomers,
49 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
50 salts of isomers, homologues, nitrogen-heterocyclic analogs,
51 esters, or ethers, if the existence of such salts, isomers, and
52 salts of isomers is possible within the specific chemical
53 designation or class description:
54 1. Alpha-Ethyltryptamine.
55 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
56 oxazoline).
57 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
58 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
59 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
60 6. Bufotenine.
61 7. Cannabis.
62 8. Cathinone.
63 9. DET (Diethyltryptamine).
64 10. 2,5-Dimethoxyamphetamine.
65 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
66 12. DMT (Dimethyltryptamine).
67 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
68 analog of phencyclidine).
69 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
70 15. N-Ethylamphetamine.
71 16. Fenethylline.
72 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
73 18. Ibogaine.
74 19. LSD (Lysergic acid diethylamide).
75 20. Mescaline.
76 21. Methcathinone.
77 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
78 23. PMA (4-Methoxyamphetamine).
79 24. PMMA (4-Methoxymethamphetamine).
80 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
81 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
82 27. MDA (3,4-Methylenedioxyamphetamine).
83 28. JB-336 (N-Methyl-3-piperidyl benzilate).
84 29. N,N-Dimethylamphetamine.
85 30. Parahexyl.
86 31. Peyote.
87 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
88 analog of phencyclidine).
89 33. Psilocybin.
90 34. Psilocyn.
91 35. Salvia divinorum, except for any drug product approved
92 by the United States Food and Drug Administration which contains
93 Salvia divinorum or its isomers, esters, ethers, salts, and
94 salts of isomers, esters, and ethers, if the existence of such
95 isomers, esters, ethers, and salts is possible within the
96 specific chemical designation.
97 36. Salvinorin A, except for any drug product approved by
98 the United States Food and Drug Administration which contains
99 Salvinorin A or its isomers, esters, ethers, salts, and salts of
100 isomers, esters, and ethers, if the existence of such isomers,
101 esters, ethers, and salts is possible within the specific
102 chemical designation.
103 37. Xylazine, except for any drug product approved by the
104 United States Food and Drug Administration which contains
105 xylazine or a compounded form of xylazine labeled for veterinary
106 use and prescribed or dispensed by a veterinarian licensed under
107 chapter 474.
108 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
109 (Thiophene analog of phencyclidine).
110 39. 3,4,5-Trimethoxyamphetamine.
111 40. Methylone (3,4-Methylenedioxymethcathinone).
112 41. MDPV (3,4-Methylenedioxypyrovalerone).
113 42. Methylmethcathinone.
114 43. Methoxymethcathinone.
115 44. Fluoromethcathinone.
116 45. Methylethcathinone.
117 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
118 yl)phenol) and its dimethyloctyl (C8) homologue.
119 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
120 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
121 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
122 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
123 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
124 naphthoyl)indole).
125 51. BZP (Benzylpiperazine).
126 52. Fluorophenylpiperazine.
127 53. Methylphenylpiperazine.
128 54. Chlorophenylpiperazine.
129 55. Methoxyphenylpiperazine.
130 56. DBZP (1,4-Dibenzylpiperazine).
131 57. TFMPP (Trifluoromethylphenylpiperazine).
132 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
133 Methylenedioxy-N-methylbutanamine).
134 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
135 60. 5-Hydroxy-N-methyltryptamine.
136 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
137 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
138 63. Methyltryptamine.
139 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
140 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
141 66. Tyramine (4-Hydroxyphenethylamine).
142 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
143 68. DiPT (N,N-Diisopropyltryptamine).
144 69. DPT (N,N-Dipropyltryptamine).
145 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
146 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
147 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
148 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
149 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
150 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
151 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
152 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
153 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
154 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
155 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
156 81. Butylone (3,4-Methylenedioxy-alpha
157 methylaminobutyrophenone).
158 82. Ethcathinone.
159 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
160 84. Naphyrone (Naphthylpyrovalerone).
161 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
162 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
163 87. 3,4-Methylenedioxy-propiophenone.
164 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
165 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
166 90. 3,4-Methylenedioxy-N-acetylcathinone.
167 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
168 92. 3,4-Methylenedioxy-N-acetylethcathinone.
169 93. Bromomethcathinone.
170 94. Buphedrone (alpha-Methylamino-butyrophenone).
171 95. Eutylone (3,4-Methylenedioxy-alpha
172 ethylaminobutyrophenone).
173 96. Dimethylcathinone.
174 97. Dimethylmethcathinone.
175 98. Pentylone (3,4-Methylenedioxy-alpha
176 methylaminovalerophenone).
177 99. MDPPP (3,4-Methylenedioxy-alpha
178 pyrrolidinopropiophenone).
179 100. MDPBP (3,4-Methylenedioxy-alpha
180 pyrrolidinobutyrophenone).
181 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
182 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
183 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
184 (Benocyclidine).
185 104. F-MABP (Fluoromethylaminobutyrophenone).
186 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
187 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
188 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
189 108. Me-EABP (Methylethylaminobutyrophenone).
190 109. Etizolam.
191 110. PPP (Pyrrolidinopropiophenone).
192 111. PBP (Pyrrolidinobutyrophenone).
193 112. PVP (Pyrrolidinovalerophenone) or
194 (Pyrrolidinopentiophenone).
195 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
196 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
197 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
198 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
199 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
200 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
201 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
202 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
203 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
204 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
205 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
206 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
207 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
208 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
209 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
210 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
211 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
212 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
213 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
214 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
215 ol).
216 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
217 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
218 methanol).
219 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
220 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
221 1,4-dione).
222 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
223 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
224 undecanamide).
225 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
226 undecanamide).
227 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
228 methyloctan-2-yl)phenol).
229 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
230 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
231 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
232 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
233 methoxyphenylacetyl)indole).
234 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
235 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
236 naphthalenylmethanone).
237 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
238 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
239 naphthalenylmethanone).
240 143. Pentedrone (alpha-Methylaminovalerophenone).
241 144. Fluoroamphetamine.
242 145. Fluoromethamphetamine.
243 146. Methoxetamine.
244 147. Methiopropamine.
245 148. Methylbuphedrone (Methyl-alpha
246 methylaminobutyrophenone).
247 149. APB ((2-Aminopropyl)benzofuran).
248 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
249 151. UR-144 (1-Pentyl-3-(2,2,3,3
250 tetramethylcyclopropanoyl)indole).
251 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
252 tetramethylcyclopropanoyl)indole).
253 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
254 tetramethylcyclopropanoyl)indole).
255 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
256 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
257 iodobenzoyl)indole).
258 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
259 carboxamide).
260 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
261 cyclohexylcarbamate).
262 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
263 cyclohexyl ester).
264 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
265 benzoxazin-4-one).
266 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
267 161. 2C-H (2,5-Dimethoxyphenethylamine).
268 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
269 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
270 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
271 methoxybenzyl)]phenethylamine).
272 165. MDMA (3,4-Methylenedioxymethamphetamine).
273 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
274 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
275 carboxylate).
276 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
277 carboxylate).
278 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
279 3-carboxamide).
280 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
281 pentylindazole-3-carboxamide).
282 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
283 (4-fluorobenzyl)indazole-3-carboxamide).
284 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
285 1-pentylindazole-3-carboxamide).
286 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
287 yl)-1-(fluoropentyl)indole-3-carboxamide).
288 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
289 methoxybenzyl)]phenethylamine).
290 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
291 methoxybenzyl)]phenethylamine).
292 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
293 (cyclohexylmethyl)indazole-3-carboxamide).
294 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
295 carboxylate).
296 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
297 3-carboxamide).
298 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
299 (fluoropentyl)indazole-3-carboxamide).
300 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
301 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
302 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
303 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
304 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
305 hexahydrobenzo[c]chromen-1-ol).
306 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
307 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
308 hexahydrobenzo[c]chromen-1-ol).
309 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
310 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
311 diol).
312 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
313 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
314 tetrahydro-6aH-benzo[c]chromen-1-ol).
315 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
316 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
317 187. MAPB ((2-Methylaminopropyl)benzofuran).
318 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
319 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
320 190. Synthetic Cannabinoids.—Unless specifically excepted
321 or unless listed in another schedule or contained within a
322 pharmaceutical product approved by the United States Food and
323 Drug Administration, any material, compound, mixture, or
324 preparation that contains any quantity of a synthetic
325 cannabinoid found to be in any of the following chemical class
326 descriptions, or homologues, nitrogen-heterocyclic analogs,
327 isomers (including optical, positional, or geometric), esters,
328 ethers, salts, and salts of homologues, nitrogen-heterocyclic
329 analogs, isomers, esters, or ethers, whenever the existence of
330 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
331 ethers, salts, and salts of isomers, esters, or ethers is
332 possible within the specific chemical class or designation.
333 Since nomenclature of these synthetically produced cannabinoids
334 is not internationally standardized and may continually evolve,
335 these structures or the compounds of these structures shall be
336 included under this subparagraph, regardless of their specific
337 numerical designation of atomic positions covered, if it can be
338 determined through a recognized method of scientific testing or
339 analysis that the substance contains properties that fit within
340 one or more of the following categories:
341 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
342 naturally contained in a plant of the genus Cannabis, the
343 synthetic equivalents of the substances contained in the plant
344 or in the resinous extracts of the genus Cannabis, or synthetic
345 substances, derivatives, and their isomers with similar chemical
346 structure and pharmacological activity, including, but not
347 limited to, Delta 9 tetrahydrocannabinols and their optical
348 isomers, Delta 8 tetrahydrocannabinols and their optical
349 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
350 isomers, or any compound containing a tetrahydrobenzo[c]chromene
351 structure with substitution at either or both the 3-position or
352 9-position, with or without substitution at the 1-position with
353 hydroxyl or alkoxy groups, including, but not limited to:
354 (I) Tetrahydrocannabinol.
355 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
356 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
357 ol).
358 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
359 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
360 ol).
361 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
362 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
363 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
364 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
365 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
366 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
367 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
368 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
369 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
370 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
371 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
372 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
373 (X) Parahexyl.
374 b. Naphthoylindoles, Naphthoylindazoles,
375 Naphthoylcarbazoles, Naphthylmethylindoles,
376 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
377 compound containing a naphthoylindole, naphthoylindazole,
378 naphthoylcarbazole, naphthylmethylindole,
379 naphthylmethylindazole, or naphthylmethylcarbazole structure,
380 with or without substitution on the indole, indazole, or
381 carbazole ring to any extent, whether or not substituted on the
382 naphthyl ring to any extent, including, but not limited to:
383 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
384 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
385 naphthoyl)indole).
386 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
387 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
388 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
389 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
390 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
391 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
392 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
393 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
394 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
395 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
396 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
397 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
398 naphthoyl)indole).
399 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
400 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
401 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
402 naphthoyl)indole).
403 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
404 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
405 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
406 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
407 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
408 naphthylmethyl]indole).
409 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
410 naphthoyl)indole).
411 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
412 naphthoyl)indole).
413 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
414 naphthoyl)indole).
415 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
416 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
417 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
418 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
419 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
420 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
421 naphthoyl)indole).
422 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
423 naphthoyl)indole).
424 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
425 naphthoyl)indole).
426 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
427 naphthoyl)indole).
428 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
429 naphthoyl)indole).
430 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
431 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
432 naphthoyl)indazole).
433 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
434 naphthoyl)indole).
435 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
436 naphthoyl)indole).
437 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
438 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
439 naphthoyl)carbazole).
440 c. Naphthoylpyrroles.—Any compound containing a
441 naphthoylpyrrole structure, with or without substitution on the
442 pyrrole ring to any extent, whether or not substituted on the
443 naphthyl ring to any extent, including, but not limited to:
444 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
445 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
446 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
447 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
448 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
449 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
450 naphthoyl)pyrrole).
451 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
452 naphthoyl)pyrrole).
453 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
454 naphthoyl)pyrrole).
455 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
456 naphthoyl)pyrrole).
457 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
458 naphthoyl)pyrrole).
459 d. Naphthylmethylenindenes.—Any compound containing a
460 naphthylmethylenindene structure, with or without substitution
461 at the 3-position of the indene ring to any extent, whether or
462 not substituted on the naphthyl ring to any extent, including,
463 but not limited to, JWH-176 (3-Pentyl-1
464 (naphthylmethylene)indene).
465 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
466 compound containing a phenylacetylindole or phenylacetylindazole
467 structure, with or without substitution on the indole or
468 indazole ring to any extent, whether or not substituted on the
469 phenyl ring to any extent, including, but not limited to:
470 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
471 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
472 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
473 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
474 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
475 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
476 (VII) Cannabipiperidiethanone.
477 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
478 methoxyphenylacetyl)indole).
479 f. Cyclohexylphenols.—Any compound containing a
480 cyclohexylphenol structure, with or without substitution at the
481 5-position of the phenolic ring to any extent, whether or not
482 substituted on the cyclohexyl ring to any extent, including, but
483 not limited to:
484 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
485 yl)phenol).
486 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
487 homologue).
488 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
489 methyloctan-2-yl)phenol).
490 g. Benzoylindoles and Benzoylindazoles.—Any compound
491 containing a benzoylindole or benzoylindazole structure, with or
492 without substitution on the indole or indazole ring to any
493 extent, whether or not substituted on the phenyl ring to any
494 extent, including, but not limited to:
495 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
496 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
497 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
498 iodo-5-nitrobenzoyl)indole).
499 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
500 methoxybenzoyl)indole).
501 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
502 iodobenzoyl)indole).
503 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
504 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
505 methoxybenzoyl)indole).
506 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
507 3-(4-methoxybenzoyl)indole).
508 h. Tetramethylcyclopropanoylindoles and
509 Tetramethylcyclopropanoylindazoles.—Any compound containing a
510 tetramethylcyclopropanoylindole or
511 tetramethylcyclopropanoylindazole structure, with or without
512 substitution on the indole or indazole ring to any extent,
513 whether or not substituted on the tetramethylcyclopropyl group
514 to any extent, including, but not limited to:
515 (I) UR-144 (1-Pentyl-3-(2,2,3,3
516 tetramethylcyclopropanoyl)indole).
517 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
518 tetramethylcyclopropanoyl)indole).
519 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
520 tetramethylcyclopropanoyl)indole).
521 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
522 tetramethylcyclopropanoyl)indole).
523 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
524 tetramethylcyclopropanoyl)indole).
525 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
526 tetramethylcyclopropanoyl)indole).
527 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
528 tetramethylcyclopropanoyl)indole).
529 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
530 tetramethylcyclopropanoyl)indazole).
531 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
532 tetramethylcyclopropanoyl)indole).
533 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
534 tetramethylcyclopropanoyl)indole).
535 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
536 carboxamides, and Adamantylindazole carboxamides.—Any compound
537 containing an adamantoyl indole, adamantoyl indazole, adamantyl
538 indole carboxamide, or adamantyl indazole carboxamide structure,
539 with or without substitution on the indole or indazole ring to
540 any extent, whether or not substituted on the adamantyl ring to
541 any extent, including, but not limited to:
542 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
543 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
544 3-carboxamide).
545 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
546 carboxamide).
547 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
548 adamantoyl)indole).
549 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
550 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
551 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
552 adamantoyl)indole).
553 j. Quinolinylindolecarboxylates,
554 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
555 and Quinolinylindazolecarboxamides.—Any compound containing a
556 quinolinylindole carboxylate, quinolinylindazole carboxylate,
557 isoquinolinylindole carboxylate, isoquinolinylindazole
558 carboxylate, quinolinylindole carboxamide, quinolinylindazole
559 carboxamide, isoquinolinylindole carboxamide, or
560 isoquinolinylindazole carboxamide structure, with or without
561 substitution on the indole or indazole ring to any extent,
562 whether or not substituted on the quinoline or isoquinoline ring
563 to any extent, including, but not limited to:
564 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
565 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
566 carboxylate).
567 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
568 carboxylate).
569 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
570 carboxylate).
571 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
572 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
573 3-carboxylate).
574 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
575 3-carboxylate).
576 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
577 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
578 carboxamide).
579 k. Naphthylindolecarboxylates and
580 Naphthylindazolecarboxylates.—Any compound containing a
581 naphthylindole carboxylate or naphthylindazole carboxylate
582 structure, with or without substitution on the indole or
583 indazole ring to any extent, whether or not substituted on the
584 naphthyl ring to any extent, including, but not limited to:
585 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
586 carboxylate).
587 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
588 carboxylate).
589 (III) Fluoro SDB-005 (1-Naphthalenyl 1
590 (fluoropentyl)indazole-3-carboxylate).
591 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
592 carboxylate).
593 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
594 carboxylate).
595 l. Naphthylindole carboxamides and Naphthylindazole
596 carboxamides.—Any compound containing a naphthylindole
597 carboxamide or naphthylindazole carboxamide structure, with or
598 without substitution on the indole or indazole ring to any
599 extent, whether or not substituted on the naphthyl ring to any
600 extent, including, but not limited to:
601 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
602 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
603 3-carboxamide).
604 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
605 (chloropentyl)indole-3-carboxamide).
606 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
607 carboxamide).
608 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
609 (fluoropentyl)indazole-3-carboxamide).
610 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
611 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
612 Alkylcarbonyl indazole carboxylates.—Any compound containing an
613 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
614 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
615 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
616 indole carboxamide, indazole carboxamide, indole carboxylate, or
617 indazole carboxylate, with or without substitution on the indole
618 or indazole ring to any extent, whether or not substituted on
619 the alkylcarbonyl group to any extent, including, but not
620 limited to:
621 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
622 pentylindole-3-carboxamide).
623 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
624 yl)-1-(fluoropentyl)indole-3-carboxamide).
625 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
626 (fluoropentyl)indole-3-carboxamide).
627 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
628 pentylindazole-3-carboxamide).
629 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
630 1-(fluoropentyl)indazole-3-carboxamide).
631 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
632 1-pentylindazole-3-carboxamide).
633 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
634 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
635 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
636 (4-fluorobenzyl)indazole-3-carboxamide).
637 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
638 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
639 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
640 (cyclohexylmethyl)indazole-3-carboxamide).
641 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
642 (cyclohexylmethyl)indazole-3-carboxamide).
643 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
644 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
645 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
646 pentylindazole-3-carboxamide).
647 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
648 (fluoropentyl)indazole-3-carboxamide).
649 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
650 fluorobenzyl)indazole-3-carboxamide).
651 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
652 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
653 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
654 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
655 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
656 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
657 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
658 fluoropentyl)indole-3-carboxamide).
659 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
660 fluoropentyl)indazole-3-carboxamide).
661 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
662 (cyclohexylmethyl)indazole-3-carboxamide).
663 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
664 fluorobenzyl)indazole-3-carboxamide).
665 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
666 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
667 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
668 Any compound containing a N-(2-phenylpropan-2-yl) indole
669 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
670 structure, with or without substitution on the indole or
671 indazole ring to any extent, whether or not substituted on the
672 phenyl ring of the cumyl group to any extent, including, but not
673 limited to:
674 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
675 carboxamide).
676 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
677 (fluoropentyl)indole-3-carboxamide).
678 o. Other Synthetic Cannabinoids.—Any material, compound,
679 mixture, or preparation that contains any quantity of a
680 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
681 (I) With or without modification or replacement of a
682 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
683 between either two core rings, or linkage between a core ring
684 and group structure, with or without the addition of a carbon or
685 replacement of a carbon;
686 (II) With or without replacement of a core ring or group
687 structure, whether or not substituted on the ring or group
688 structures to any extent; and
689 (III) Is a cannabinoid receptor agonist, unless
690 specifically excepted or unless listed in another schedule or
691 contained within a pharmaceutical product approved by the United
692 States Food and Drug Administration.
693 191. Substituted Cathinones.—Unless specifically excepted,
694 listed in another schedule, or contained within a pharmaceutical
695 product approved by the United States Food and Drug
696 Administration, any material, compound, mixture, or preparation,
697 including its salts, isomers, esters, or ethers, and salts of
698 isomers, esters, or ethers, whenever the existence of such salts
699 is possible within any of the following specific chemical
700 designations:
701 a. Any compound containing a 2-amino-1-phenyl-1-propanone
702 structure;
703 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
704 structure; or
705 c. Any compound containing a 2-amino-1-thiophenyl-1
706 propanone structure,
707
708 whether or not the compound is further modified:
709 (I) With or without substitution on the ring system to any
710 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
711 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
712 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
713 substituents;
714 (II) With or without substitution at the 3-propanone
715 position with an alkyl substituent or removal of the methyl
716 group at the 3-propanone position;
717 (III) With or without substitution at the 2-amino nitrogen
718 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
719 not further substituted in the ring system; or
720 (IV) With or without inclusion of the 2-amino nitrogen atom
721 in a cyclic structure, including, but not limited to:
722 (A) Methcathinone.
723 (B) Ethcathinone.
724 (C) Methylone (3,4-Methylenedioxymethcathinone).
725 (D) 2,3-Methylenedioxymethcathinone.
726 (E) MDPV (3,4-Methylenedioxypyrovalerone).
727 (F) Methylmethcathinone.
728 (G) Methoxymethcathinone.
729 (H) Fluoromethcathinone.
730 (I) Methylethcathinone.
731 (J) Butylone (3,4-Methylenedioxy-alpha
732 methylaminobutyrophenone).
733 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
734 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
735 (M) Naphyrone (Naphthylpyrovalerone).
736 (N) Bromomethcathinone.
737 (O) Buphedrone (alpha-Methylaminobutyrophenone).
738 (P) Eutylone (3,4-Methylenedioxy-alpha
739 ethylaminobutyrophenone).
740 (Q) Dimethylcathinone.
741 (R) Dimethylmethcathinone.
742 (S) Pentylone (3,4-Methylenedioxy-alpha
743 methylaminovalerophenone).
744 (T) Pentedrone (alpha-Methylaminovalerophenone).
745 (U) MDPPP (3,4-Methylenedioxy-alpha
746 pyrrolidinopropiophenone).
747 (V) MDPBP (3,4-Methylenedioxy-alpha
748 pyrrolidinobutyrophenone).
749 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
750 (X) PPP (Pyrrolidinopropiophenone).
751 (Y) PVP (Pyrrolidinovalerophenone) or
752 (Pyrrolidinopentiophenone).
753 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
754 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
755 (BB) F-MABP (Fluoromethylaminobutyrophenone).
756 (CC) Me-EABP (Methylethylaminobutyrophenone).
757 (DD) PBP (Pyrrolidinobutyrophenone).
758 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
759 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
760 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
761 (HH) Dimethylone (3,4-Methylenedioxy-N,N
762 dimethylcathinone).
763 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
764 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
765 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
766 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
767 (MM) Methylbuphedrone (Methyl-alpha
768 methylaminobutyrophenone).
769 (NN) Methyl-alpha-methylaminohexanophenone.
770 (OO) N-Ethyl-N-methylcathinone.
771 (PP) PHP (Pyrrolidinohexanophenone).
772 (QQ) PV8 (Pyrrolidinoheptanophenone).
773 (RR) Chloromethcathinone.
774 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
775 192. Substituted Phenethylamines.—Unless specifically
776 excepted or unless listed in another schedule, or contained
777 within a pharmaceutical product approved by the United States
778 Food and Drug Administration, any material, compound, mixture,
779 or preparation, including its salts, isomers, esters, or ethers,
780 and salts of isomers, esters, or ethers, whenever the existence
781 of such salts is possible within any of the following specific
782 chemical designations, any compound containing a phenethylamine
783 structure, without a beta-keto group, and without a benzyl group
784 attached to the amine group, whether or not the compound is
785 further modified with or without substitution on the phenyl ring
786 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
787 halide, fused alkylenedioxy, fused furan, fused benzofuran,
788 fused dihydrofuran, or fused tetrahydropyran substituents,
789 whether or not further substituted on a ring to any extent, with
790 or without substitution at the alpha or beta position by any
791 alkyl substituent, with or without substitution at the nitrogen
792 atom, and with or without inclusion of the 2-amino nitrogen atom
793 in a cyclic structure, including, but not limited to:
794 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
795 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
796 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
797 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
798 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
799 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
800 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
801 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
802 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
803 j. 2C-H (2,5-Dimethoxyphenethylamine).
804 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
805 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
806 m. MDMA (3,4-Methylenedioxymethamphetamine).
807 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
808 Methylenedioxy-N-methylbutanamine).
809 o. MDA (3,4-Methylenedioxyamphetamine).
810 p. 2,5-Dimethoxyamphetamine.
811 q. Fluoroamphetamine.
812 r. Fluoromethamphetamine.
813 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
814 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
815 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
816 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
817 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
818 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
819 y. PMA (4-Methoxyamphetamine).
820 z. N-Ethylamphetamine.
821 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
822 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
823 cc. PMMA (4-Methoxymethamphetamine).
824 dd. N,N-Dimethylamphetamine.
825 ee. 3,4,5-Trimethoxyamphetamine.
826 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
827 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
828 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
829 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
830 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
831 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
832 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
833 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
834 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
835 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
836 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
837 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
838 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
839 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
840 dihydrobenzofuran),
841
842 which does not include phenethylamine, mescaline as described in
843 subparagraph 20., substituted cathinones as described in
844 subparagraph 191., N-Benzyl phenethylamine compounds as
845 described in subparagraph 193., or methamphetamine as described
846 in subparagraph (2)(c)5.
847 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
848 excepted or unless listed in another schedule, or contained
849 within a pharmaceutical product approved by the United States
850 Food and Drug Administration, any material, compound, mixture,
851 or preparation, including its salts, isomers, esters, or ethers,
852 and salts of isomers, esters, or ethers, whenever the existence
853 of such salts is possible within any of the following specific
854 chemical designations, any compound containing a phenethylamine
855 structure without a beta-keto group, with substitution on the
856 nitrogen atom of the amino group with a benzyl substituent, with
857 or without substitution on the phenyl or benzyl ring to any
858 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
859 alkylenedioxy, fused furan, fused benzofuran, or fused
860 tetrahydropyran substituents, whether or not further substituted
861 on a ring to any extent, with or without substitution at the
862 alpha position by any alkyl substituent, including, but not
863 limited to:
864 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
865 methoxybenzyl)]phenethylamine).
866 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
867 hydroxybenzyl)]phenethylamine).
868 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
869 fluorobenzyl)]phenethylamine).
870 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
871 methylenedioxybenzyl)]phenethylamine).
872 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
873 methoxybenzyl)]phenethylamine).
874 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
875 hydroxybenzyl)]phenethylamine).
876 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
877 fluorobenzyl)]phenethylamine).
878 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
879 methylenedioxybenzyl)]phenethylamine).
880 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
881 methoxybenzyl)]phenethylamine).
882 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
883 methoxybenzyl)]phenethylamine).
884 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
885 methoxybenzyl)]phenethylamine).
886 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
887 methoxybenzyl)]phenethylamine).
888 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
889 hydroxybenzyl)]phenethylamine).
890 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
891 fluorobenzyl)]phenethylamine).
892 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
893 methylenedioxybenzyl)]phenethylamine).
894 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
895 methoxybenzyl)]phenethylamine).
896 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
897 hydroxybenzyl)]phenethylamine).
898 r. 25H-NBF (2,5-Dimethoxy-[N-(2
899 fluorobenzyl)]phenethylamine).
900 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
901 methoxybenzyl)]phenethylamine),
902
903 which does not include substituted cathinones as described in
904 subparagraph 191.
905 194. Substituted Tryptamines.—Unless specifically excepted
906 or unless listed in another schedule, or contained within a
907 pharmaceutical product approved by the United States Food and
908 Drug Administration, any material, compound, mixture, or
909 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
910 example tryptamine, structure with or without mono- or di
911 substitution of the amine nitrogen with alkyl or alkenyl groups,
912 or by inclusion of the amino nitrogen atom in a cyclic
913 structure, whether or not substituted at the alpha position with
914 an alkyl group, whether or not substituted on the indole ring to
915 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
916 groups, including, but not limited to:
917 a. Alpha-Ethyltryptamine.
918 b. Bufotenine.
919 c. DET (Diethyltryptamine).
920 d. DMT (Dimethyltryptamine).
921 e. MET (N-Methyl-N-ethyltryptamine).
922 f. DALT (N,N-Diallyltryptamine).
923 g. EiPT (N-Ethyl-N-isopropyltryptamine).
924 h. MiPT (N-Methyl-N-isopropyltryptamine).
925 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
926 j. 5-Hydroxy-N-methyltryptamine.
927 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
928 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
929 m. Methyltryptamine.
930 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
931 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
932 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
933 q. DiPT (N,N-Diisopropyltryptamine).
934 r. DPT (N,N-Dipropyltryptamine).
935 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
936 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
937 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
938 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
939 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
940 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
941 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
942 isopropyltryptamine).
943 z. Methyl-alpha-ethyltryptamine.
944 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
945
946 which does not include tryptamine, psilocyn as described in
947 subparagraph 34., or psilocybin as described in subparagraph 33.
948 195. Substituted Phenylcyclohexylamines.—Unless
949 specifically excepted or unless listed in another schedule, or
950 contained within a pharmaceutical product approved by the United
951 States Food and Drug Administration, any material, compound,
952 mixture, or preparation containing a phenylcyclohexylamine
953 structure, with or without any substitution on the phenyl ring,
954 any substitution on the cyclohexyl ring, any replacement of the
955 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
956 without substitution on the amine with alkyl, dialkyl, or alkoxy
957 substituents, inclusion of the nitrogen in a cyclic structure,
958 or any combination of the above, including, but not limited to:
959 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
960 (Benocyclidine).
961 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
962 of phencyclidine).
963 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
964 analog of phencyclidine).
965 d. PCPr (Phenylcyclohexylpropylamine).
966 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
967 analog of phencyclidine).
968 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
969 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
970 h. Methoxetamine.
971 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
972 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
973 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
974 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
975 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
976 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
977 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
978 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
979 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
980 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
981 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
982 piperidinylidene]-benzenesulfonamide.
983 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
984 piperidinylidene]-benzenesulfonamide.
985 198. AH-7921, 3,4-dichloro-N-[[1
986 (dimethylamino)cyclohexyl]methyl]-benzamide.
987 199. U47700, trans-3,4-dichloro-N-[2
988 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
989 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
990 dihydrochloride.
991 (3) SCHEDULE III.—A substance in Schedule III has a
992 potential for abuse less than the substances contained in
993 Schedules I and II and has a currently accepted medical use in
994 treatment in the United States, and abuse of the substance may
995 lead to moderate or low physical dependence or high
996 psychological dependence or, in the case of anabolic steroids,
997 may lead to physical damage. The following substances are
998 controlled in Schedule III:
999 (a) Unless specifically excepted or unless listed in
1000 another schedule, any material, compound, mixture, or
1001 preparation which contains any quantity of the following
1002 substances having a depressant or stimulant effect on the
1003 nervous system:
1004 1. Any substance which contains any quantity of a
1005 derivative of barbituric acid, including thiobarbituric acid, or
1006 any salt of a derivative of barbituric acid or thiobarbituric
1007 acid, including, but not limited to, butabarbital and
1008 butalbital.
1009 2. Benzphetamine.
1010 3. Buprenorphine.
1011 4. Chlorhexadol.
1012 5. Chlorphentermine.
1013 6. Clortermine.
1014 7. Embutramide.
1015 8. Lysergic acid.
1016 9. Lysergic acid amide.
1017 10. Methyprylon.
1018 11. Perampanel.
1019 12. Phendimetrazine.
1020 13. Sulfondiethylmethane.
1021 14. Sulfonethylmethane.
1022 15. Sulfonmethane.
1023 16. Tiletamine and zolazepam or any salt thereof.
1024 17. Xylazine, except for any drug product approved by the
1025 United States Food and Drug Administration which contains
1026 xylazine or a compounded form of xylazine labeled for veterinary
1027 use, which product is prescribed or dispensed by a veterinarian
1028 licensed under chapter 474 or labeled and dispensed by a
1029 veterinarian licensed under chapter 474 or a pharmacy registered
1030 in this state pursuant to a prescription from a veterinarian
1031 licensed under chapter 474 who possesses xylazine for:
1032 a. An animal owned by or under a veterinarian’s care. As
1033 used in this sub-subparagraph, the term “veterinarian” includes
1034 a government agency or business where animals are located, and
1035 an employee or agent of an agency or business acting within the
1036 scope of their employment or agency.
1037 b. Use in governmental animal-control programs authorized
1038 under applicable federal, state, local, or tribal law.
1039 c. Use in wildlife programs authorized under applicable
1040 federal, state, local, or tribal law.
1041 Section 2. Paragraph (i) of subsection (1) of section
1042 893.13, Florida Statutes, is amended to read:
1043 893.13 Prohibited acts; penalties.—
1044 (1)
1045 (i) Except as authorized by this chapter, a person commits
1046 a felony of the first degree, punishable as provided in s.
1047 775.082, s. 775.083, or s. 775.084, and must be sentenced to a
1048 mandatory minimum term of imprisonment of 3 years, if:
1049 1. The person sells, manufactures, or delivers, or
1050 possesses with intent to sell, manufacture, or deliver, any of
1051 the following:
1052 a. Alfentanil, as described in s. 893.03(2)(b)1.;
1053 b. Carfentanil, as described in s. 893.03(2)(b)6.;
1054 c. Fentanyl, as described in s. 893.03(2)(b)9.;
1055 d. Sufentanil, as described in s. 893.03(2)(b)30.;
1056 e. A fentanyl derivative, as described in s.
1057 893.03(1)(a)63.;
1058 f. Xylazine, as described in s. 893.03(1)(c)37.;
1059 g. A controlled substance analog, as described in s.
1060 893.0356, of any substance described in sub-subparagraphs a.-f.
1061 sub-subparagraphs a.-e.; or
1062 h.g. A mixture containing any substance described in sub
1063 subparagraphs a.-g. sub-subparagraphs a.-f.; and
1064 2. The substance or mixture listed in subparagraph 1. is in
1065 a form that resembles, or is mixed, granulated, absorbed, spray
1066 dried, or aerosolized as or onto, coated on, in whole or in
1067 part, or solubilized with or into, a product, when such product
1068 or its packaging further has at least one of the following
1069 attributes:
1070 a. Resembles the trade dress of a branded food product,
1071 consumer food product, or logo food product;
1072 b. Incorporates an actual or fake registered copyright,
1073 service mark, or trademark;
1074 c. Resembles candy, cereal, a gummy, a vitamin, or a
1075 chewable product, such as a gum or gelatin-based product; or
1076 d. Contains a cartoon character imprint.
1077 Section 3. Paragraph (c) of subsection (1) of section
1078 893.135, Florida Statutes, is amended to read:
1079 893.135 Trafficking; mandatory sentences; suspension or
1080 reduction of sentences; conspiracy to engage in trafficking.—
1081 (1) Except as authorized in this chapter or in chapter 499
1082 and notwithstanding the provisions of s. 893.13:
1083 (c)1. A person who knowingly sells, purchases,
1084 manufactures, delivers, or brings into this state, or who is
1085 knowingly in actual or constructive possession of, 4 grams or
1086 more of any morphine, opium, hydromorphone, or any salt,
1087 derivative, isomer, or salt of an isomer thereof, including
1088 heroin, as described in s. 893.03(1)(b), (2)(a), (3)(c)3., or
1089 (3)(c)4., or 4 grams or more of any mixture containing any such
1090 substance, but less than 30 kilograms of such substance or
1091 mixture, commits a felony of the first degree, which felony
1092 shall be known as “trafficking in illegal drugs,” punishable as
1093 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1094 quantity involved:
1095 a. Is 4 grams or more, but less than 14 grams, such person
1096 shall be sentenced to a mandatory minimum term of imprisonment
1097 of 3 years and shall be ordered to pay a fine of $50,000.
1098 b. Is 14 grams or more, but less than 28 grams, such person
1099 shall be sentenced to a mandatory minimum term of imprisonment
1100 of 15 years and shall be ordered to pay a fine of $100,000.
1101 c. Is 28 grams or more, but less than 30 kilograms, such
1102 person shall be sentenced to a mandatory minimum term of
1103 imprisonment of 25 years and shall be ordered to pay a fine of
1104 $500,000.
1105 2. A person who knowingly sells, purchases, manufactures,
1106 delivers, or brings into this state, or who is knowingly in
1107 actual or constructive possession of, 28 grams or more of
1108 hydrocodone, as described in s. 893.03(2)(a)1.k., codeine, as
1109 described in s. 893.03(2)(a)1.g., or any salt thereof, or 28
1110 grams or more of any mixture containing any such substance,
1111 commits a felony of the first degree, which felony shall be
1112 known as “trafficking in hydrocodone,” punishable as provided in
1113 s. 775.082, s. 775.083, or s. 775.084. If the quantity involved:
1114 a. Is 28 grams or more, but less than 50 grams, such person
1115 shall be sentenced to a mandatory minimum term of imprisonment
1116 of 3 years and shall be ordered to pay a fine of $50,000.
1117 b. Is 50 grams or more, but less than 100 grams, such
1118 person shall be sentenced to a mandatory minimum term of
1119 imprisonment of 7 years and shall be ordered to pay a fine of
1120 $100,000.
1121 c. Is 100 grams or more, but less than 300 grams, such
1122 person shall be sentenced to a mandatory minimum term of
1123 imprisonment of 15 years and shall be ordered to pay a fine of
1124 $500,000.
1125 d. Is 300 grams or more, but less than 30 kilograms, such
1126 person shall be sentenced to a mandatory minimum term of
1127 imprisonment of 25 years and shall be ordered to pay a fine of
1128 $750,000.
1129 3. A person who knowingly sells, purchases, manufactures,
1130 delivers, or brings into this state, or who is knowingly in
1131 actual or constructive possession of, 7 grams or more of
1132 oxycodone, as described in s. 893.03(2)(a)1.q., or any salt
1133 thereof, or 7 grams or more of any mixture containing any such
1134 substance, commits a felony of the first degree, which felony
1135 shall be known as “trafficking in oxycodone,” punishable as
1136 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1137 quantity involved:
1138 a. Is 7 grams or more, but less than 14 grams, such person
1139 shall be sentenced to a mandatory minimum term of imprisonment
1140 of 3 years and shall be ordered to pay a fine of $50,000.
1141 b. Is 14 grams or more, but less than 25 grams, such person
1142 shall be sentenced to a mandatory minimum term of imprisonment
1143 of 7 years and shall be ordered to pay a fine of $100,000.
1144 c. Is 25 grams or more, but less than 100 grams, such
1145 person shall be sentenced to a mandatory minimum term of
1146 imprisonment of 15 years and shall be ordered to pay a fine of
1147 $500,000.
1148 d. Is 100 grams or more, but less than 30 kilograms, such
1149 person shall be sentenced to a mandatory minimum term of
1150 imprisonment of 25 years and shall be ordered to pay a fine of
1151 $750,000.
1152 4.a. A person who knowingly sells, purchases, manufactures,
1153 delivers, or brings into this state, or who is knowingly in
1154 actual or constructive possession of, 4 grams or more of:
1155 (I) Alfentanil, as described in s. 893.03(2)(b)1.;
1156 (II) Carfentanil, as described in s. 893.03(2)(b)6.;
1157 (III) Fentanyl, as described in s. 893.03(2)(b)9.;
1158 (IV) Sufentanil, as described in s. 893.03(2)(b)30.;
1159 (V) A fentanyl derivative, as described in s.
1160 893.03(1)(a)63.;
1161 (VI) A controlled substance analog, as described in s.
1162 893.0356, of any substance described in sub-sub-subparagraphs
1163 (I)-(V); or
1164 (VII) A mixture containing any substance described in sub
1165 sub-subparagraphs (I)-(VI),
1166
1167 commits a felony of the first degree, which felony shall be
1168 known as “trafficking in dangerous fentanyl or fentanyl
1169 analogues,” punishable as provided in s. 775.082, s. 775.083, or
1170 s. 775.084.
1171 b. If the quantity involved under sub-subparagraph a.:
1172 (I) Is 4 grams or more, but less than 14 grams, such person
1173 shall be sentenced to a mandatory minimum term of imprisonment
1174 of 7 years, and shall be ordered to pay a fine of $50,000.
1175 (II) Is 14 grams or more, but less than 28 grams, such
1176 person shall be sentenced to a mandatory minimum term of
1177 imprisonment of 20 years, and shall be ordered to pay a fine of
1178 $100,000.
1179 (III) Is 28 grams or more, such person shall be sentenced
1180 to a mandatory minimum term of imprisonment of 25 years, and
1181 shall be ordered to pay a fine of $500,000.
1182 c. A person 18 years of age or older who violates sub
1183 subparagraph a. by knowingly selling or delivering to a minor at
1184 least 4 grams of a substance or mixture listed in sub
1185 subparagraph a. shall be sentenced to a mandatory minimum term
1186 of not less than 25 years and not exceeding life imprisonment,
1187 and shall be ordered to pay a fine of $1 million if the
1188 substance or mixture listed in sub-subparagraph a. is in a form
1189 that resembles, or is mixed, granulated, absorbed, spray-dried,
1190 or aerosolized as or onto, coated on, in whole or in part, or
1191 solubilized with or into, a product, when such product or its
1192 packaging further has at least one of the following attributes:
1193 (I) Resembles the trade dress of a branded food product,
1194 consumer food product, or logo food product;
1195 (II) Incorporates an actual or fake registered copyright,
1196 service mark, or trademark;
1197 (III) Resembles candy, cereal, a gummy, a vitamin, or a
1198 chewable product, such as a gum or gelatin-based product; or
1199 (IV) Contains a cartoon character imprint.
1200 5. A person who knowingly sells, purchases, manufactures,
1201 delivers, or brings into this state, or who is knowingly in
1202 actual or constructive possession of, 30 kilograms or more of
1203 any morphine, opium, oxycodone, hydrocodone, codeine,
1204 hydromorphone, or any salt, derivative, isomer, or salt of an
1205 isomer thereof, including heroin, as described in s.
1206 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or 30 kilograms or
1207 more of any mixture containing any such substance, commits the
1208 first degree felony of trafficking in illegal drugs. A person
1209 who has been convicted of the first degree felony of trafficking
1210 in illegal drugs under this subparagraph shall be punished by
1211 life imprisonment and is ineligible for any form of
1212 discretionary early release except pardon or executive clemency
1213 or conditional medical release under s. 947.149. However, if the
1214 court determines that, in addition to committing any act
1215 specified in this paragraph:
1216 a. The person intentionally killed an individual or
1217 counseled, commanded, induced, procured, or caused the
1218 intentional killing of an individual and such killing was the
1219 result; or
1220 b. The person’s conduct in committing that act led to a
1221 natural, though not inevitable, lethal result,
1222
1223 such person commits the capital felony of trafficking in illegal
1224 drugs, punishable as provided in ss. 775.082 and 921.142. A
1225 person sentenced for a capital felony under this paragraph shall
1226 also be sentenced to pay the maximum fine provided under
1227 subparagraph 1.
1228 6. A person who knowingly brings into this state 60
1229 kilograms or more of any morphine, opium, oxycodone,
1230 hydrocodone, codeine, hydromorphone, or any salt, derivative,
1231 isomer, or salt of an isomer thereof, including heroin, as
1232 described in s. 893.03(1)(b), (2)(a), (3)(c)3., or (3)(c)4., or
1233 60 kilograms or more of any mixture containing any such
1234 substance, and who knows that the probable result of such
1235 importation would be the death of a person, commits capital
1236 importation of illegal drugs, a capital felony punishable as
1237 provided in ss. 775.082 and 921.142. A person sentenced for a
1238 capital felony under this paragraph shall also be sentenced to
1239 pay the maximum fine provided under subparagraph 1.
1240 7. A person who knowingly sells, purchases, manufactures,
1241 delivers, or brings into this state, or who is knowingly in
1242 actual or constructive possession of, 4 grams or more of
1243 xylazine, as described in s. 893.03(1)(c)37., or any salt
1244 thereof, or 4 grams or more of any mixture containing any such
1245 substance, commits a felony of the first degree, which felony
1246 shall be known as “trafficking in xylazine,” punishable as
1247 provided in s. 775.082, s. 775.083, or s. 775.084. If the
1248 quantity involved:
1249 a. Is 4 grams or more, but less than 14 grams, such person
1250 shall be sentenced to a mandatory minimum term of imprisonment
1251 of 7 years and shall be ordered to pay a fine of $50,000.
1252 b. Is 14 grams or more, but less than 28 grams, such person
1253 shall be sentenced to a mandatory minimum term of imprisonment
1254 of 20 years and shall be ordered to pay a fine of $100,000.
1255 c. Is 28 grams or more, such person shall be sentenced to a
1256 mandatory minimum term of imprisonment of 25 years and shall be
1257 ordered to pay a fine of $500,000.
1258 Section 4. This act shall take effect October 1, 2025.